Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
66 Leser
Artikel bewerten:
(0)

Documentary 'The Scientist' About Lifetime Achievements of Prof. Raphael Mechoulam

TEL AVIV, Israel, December 28, 2015 /PRNewswire/ --

The Film Focuses on Professor's Pioneering Work with Cannabis and the discovery of the Endocannabinoid System

'The Scientist' a documentary by filmmaker Zach Klein aims to promote the work of Professor Raphael Mechoulam. It was released on July 24th with new languages added every month.

Filmmaker Zach Klein first met Professor Mechoulam when researching the ways in which Cannabis reduced the symptoms of chemotherapy that his mother was experiencing while being treated for breast cancer. The resulting documentary follows Professor Mechoulam's attempt to answer the potent question: Are we missing something?

While the work of Dr. Mechoulam in the Cannabis field started way back in 1960, he maintained a humble attitude when it comes to the diffusion to the general public of the incredible discoveries he was able to publish. Only a few years ago Dr. Mechoulam agreed to grant an exclusive right to Zach Klein to produce a documentary about his lifetime achievements, to help spread the word and reach out to patients that suffer from medical conditions that can be treated with cannabinoids.

"Here we have a group of compounds, an endogenous system of major importance, it is not being used as much as it should be in the clinic, it is of great promise in the clinic. Let's try to push it forward and maybe this film can push it forward a bit," explained Dr. Mechoulam.

"The Scientist" was produced, over period of 4 years, in association with Fundación CANNA, a non-profit research foundation focusing on the study of Cannabis and its compounds. (http://www.fundacion-canna.es)

"The Scientist" is FREE to watch online through Youtube and the webpage of the documentary http://www.mechoulamthemovie.com, or by visiting the Fundación CANNA website athttp://www.fundacion-canna.es

Professor Mechoulam has been investigating Cannabis in medicine for longer than any other scientist and is today recognized as the founding father in the field of cannabinoid research. The Scientist traces his story from his early days as a child of the Holocaust in Bulgaria, through his immigration to Israel, and his career as the chief investigator into the chemistry and biology of the world's most misunderstood plant.

Professor Mechoulam has ascertained that THC interacts with the largest receptor system in the human body, the endocannabinoid system (ECS).

Though still unknown to most medical professionals because of the prohibition of marijuana, the importance of the 'endocannabinoid system' is growing daily. It is a system that has been called the 'supercomputer that regulates homeostasis in the human body.'

Because receptors are found throughout the brain and in every major organ, this system is thought to be involved in most disease states. This is one reason that Cannabis treats so many varied illnesses. Without his discovery, treating child epilepsy with CBD would not have been possible and Professor Mechoulam is promoted by some to win a Nobel Prize.

Professor Mechoulam has unearthed Cannabis's role in treating seizure disorders, schizophrenia and PTSD. Despite such accolades, Professor Mechoulam's name isn't known outside of a small group of researchers.

Enquiries: Zach Klein, Producer, email: info@mechoulamthescientist.com

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.